Centessa Pharmaceuticals plc

Report azionario NasdaqGS:CNTA

Capitalizzazione di mercato: US$6.3b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Centessa Pharmaceuticals Gestione

Criteri Gestione verificati 2/4

Centessa Pharmaceuticals Il CEO è Mario Accardi, nominato in Jan2026, ha un mandato di meno di un anno. possiede direttamente 0.16% delle azioni della società, per un valore di $ 9.85M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2 anni e 5.3 anni.

Informazioni chiave

Mario Accardi

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEOn/a
Mandato del CEOless than a year
Proprietà del CEO0.2%
Durata media del management2yrs
Durata media del Consiglio di amministrazione5.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Articolo di analisi • Oct 28

Health Check: How Prudently Does Centessa Pharmaceuticals (NASDAQ:CNTA) Use Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • Dec 31

Centessa Pharmaceuticals: Orexin Franchise Worth Monitoring

Summary Centessa Pharmaceuticals, founded from the merger of 10 biotech companies, is based on an asset-centric model, primarily developing its lead orexin agonist, ORX-750. ORX-750 targets narcolepsy types 1 and 2 and idiopathic hypersomnia, showing promising phase 1 results, with phase 2 data expected in 2025. Takeda's TAK-861 success partially de-risks ORX-750, making Centessa a potential acquisition target if ORX-750 proves it is best-in-class. With $500M in cash and a runway into mid-2027, Centessa's phase 2 trial results for ORX-750 are crucial for its future valuation. Read the full article on Seeking Alpha
Seeking Alpha • Sep 25

Centessa Pharmaceuticals: Progressing SerpinPC Through Registrational Trials In Hemophilia B

Summary Centessa Pharma's SerpinPC, a subcutaneous biologic inhibitor, shows promising results in reducing bleeding rates in hemophilia B, with a favorable safety profile. Despite the stock doubling in value, I remain cautious due to the company's unclear business strategy and lack of registrational data. The hemophilia B market is competitive with existing treatments. SerpinPC's unique mechanism and delivery method provide niche advantages but face significant competition. With a $2bn market cap and a cash runway of 6-7 quarters, I will avoid investing until there's more clarity on their strategic direction. Read the full article on Seeking Alpha
Seeking Alpha • Apr 24

Centessa: Hemophilia B Data Readout In 2024 Is Major Turning Point

Summary Centessa Pharmaceuticals plc interim data from the PRESent-2 study, using SerpinPC for the treatment of patients with Hemophilia B without inhibitors, is expected to be released in 2024. PRESent-3 is another registrational study using SerpinPC for the treatment of patients with Hemophilia B, however it is for the targeting of such patients with inhibitors. ORX750 is an oral selective orexin receptor agonist being developed for the treatment of patients with Narcolepsy Type 1; Proof of concept data to be released in second half 2024. LB101 is another product in the pipeline with great potential targeting solid tumors, because it utilizes proven targeted proteins such as PD-L1 and CD47; The PD-L1 blockade occurs first as a block mechanism then with hinges dissolving moves the CD47 into place to perform mechanism of action. Read the full article on Seeking Alpha
Seeking Alpha • Oct 20

Centessa Pharmaceuticals snaps multi-day losing streak; up 10%

For the first time since Oct. 13, Centessa Pharmaceuticals (NASDAQ:CNTA) is showing gains. In Thursday afternoon trading, the biotech is up 10%. There is no news or other catalysts that might explain the jump. However, based on a technical analysis, Centessa (CNTA) deviated two standard deviations lower from its mean touching its lower Bolinger Band level and has snapped up higher, back to its mean level. From market close Oct. 13 through market close Oct. 19, shares fell ~15%. Seeking Alpha views Centessa (CNTA) as a hold with high marks for valuation and growth.
Seeking Alpha • Sep 14

Centessa hemophilia B therapy SerpinPC gets FDA orphan drug status

The U.S. Food and Drug Administration (FDA) granted orphan drug designation to Centessa Pharmaceuticals' (NASDAQ:CNTA) SerpinPC to treat hemophilia B. The U.K.-based company said in a Sept. 14 press release that it plans to begin registrational studies of SerpinPC in Q4 2022. SerpinPC is a biological drug candidate, based on the serpin family of proteins which is designed to allow more thrombin to be generated by inhibiting activated protein C (APC), thus rebalancing coagulation in patients with hemophilia, according to Centessa. "We believe SerpinPC has the potential to offer patients with hemophilia B a convenient subcutaneous option that is designed to prevent and reduce bleeds without the risk of thrombosis," said Centessa CEO Saurabh Saha. The FDA grants orphan drug status to therapies which treat or prevent rare diseases that affect fewer than 200K people in the U.S. The designation provides certain incentives, including up to seven years of market exclusivity, if approved.
Seeking Alpha • Aug 10

Centessa Pharmaceuticals GAAP EPS of -$0.69

Centessa Pharmaceuticals press release (NASDAQ:CNTA): Q2 GAAP EPS of -$0.69. Cash and Cash Equivalents: $484.2 million as of June 30, 2022, which the Company expects will fund operations into 2026, without drawing on the remaining available tranches under the Oberland credit facility.
Seeking Alpha • Dec 23

Checking In On Centessa Pharmaceuticals

Today, we put Centessa Pharmaceuticals in the spotlight for the first time. Centessa has a unique business model, multiple potential shots on goal, is deep in Busted IPO territory and has picked up some recent insider buying. A full investment analysis follows in the paragraphs below.

AMMINISTRATORE DELEGATO

Mario Accardi (40 yo)

less than a year
Mandato

Dr. Mario Alberto Accardi, Ph D., MENG, is Co-Founder, Chairman & Director of Orthonika Limited. He was CEO of Orthonika Limited.He served as President of the Orexin Program at Centessa Pharmaceuticals pl...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
John Crowley
Chief Financial Officer2yrsUS$3.84m0%
$ 0
Stephen Kanes
Head of R&D and Chief Medical Officer1.4yrsUS$6.82m0%
$ 0
Mario Accardi
CEO & Directorless than a yearNessun dato0.16%
$ 9.9m
Raphael Deferiere
Senior VP & Chief Accounting Officer1.1yrsNessun datoNessun dato
Tia Bush
Chief Technology & Quality Officer3.3yrsNessun dato0.054%
$ 3.4m
Kristen Sheppard
Senior Vice President of Investor Relations & Corporate Communications4yrsNessun datoNessun dato
Iqbal Hussain
Chief Legal Officer5.3yrsUS$2.05m0.016%
$ 1.0m
Karen Anderson
Chief People Officer3.6yrsNessun dato0.043%
$ 2.7m
Gregory Weinhoff
Chief Business Officer2yrsUS$3.31m0%
$ 0
Charlene Stoudt
Senior Vice President of Clinical Development Operations1.7yrsNessun datoNessun dato
Kimberly McCormick
Senior Vice President of Regulatory Affairs & Medical Writing1.4yrsNessun datoNessun dato
2.0yrs
Durata media
53.5yo
Età media

Gestione esperta: Il team dirigenziale di CNTA è considerato esperto (durata media dell'incarico 2 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Mario Accardi
CEO & Directorless than a yearNessun dato0.16%
$ 9.9m
Francesco de Rubertis
Independent Non-Executive Chairman of the Board5.6yrsNessun datoNessun dato
Mary Hedley
Independent Non-Executive Director5.3yrsUS$404.64k0%
$ 0
Brett I. Zbar
Independent Non-Executive Director5.4yrsUS$409.64k0%
$ 0
Arjun Goyal
Independent Non-Executive Director5.4yrsUS$412.14k0.30%
$ 18.7m
Samarth Kulkarni
Independent Non-Executive Director5.3yrsUS$407.14k0%
$ 0
Carol Stuckley
Independent Non-Executive Director5.1yrsUS$414.64k0%
$ 0
Mathias Hukkelhoven
Independent Non-Executive Director3.9yrsUS$399.64k0%
$ 0
5.3yrs
Durata media
55yo
Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CNTA sono considerati esperti (durata media dell'incarico 5.3 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/06/25 10:06
Prezzo dell'azione a fine giornata2026/06/23 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Centessa Pharmaceuticals plc è coperta da 11 analisti. 8 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Mayank MamtaniB. Riley Securities, Inc.
Umer RaffatEvercore ISI
Andrea NewkirkGoldman Sachs